512 — Grand Pharmaceutical Balance Sheet
0.000.00%
- HK$23.74bn
- HK$27.06bn
- HK$11.64bn
Annual balance sheet for Grand Pharmaceutical, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,866 | 2,483 | 2,112 | 2,779 | 2,067 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,149 | 2,207 | 2,686 | 3,285 | 4,734 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6,779 | 6,887 | 7,016 | 8,026 | 8,308 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,802 | 3,942 | 3,986 | 4,266 | 4,824 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 21,057 | 22,371 | 22,515 | 24,991 | 27,167 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5,566 | 6,455 | 5,731 | 6,573 | 7,317 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7,664 | 8,231 | 7,358 | 8,518 | 10,150 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 13,393 | 14,140 | 15,158 | 16,473 | 17,017 |
| Total Liabilities & Shareholders' Equity | 21,057 | 22,371 | 22,515 | 24,991 | 27,167 |
| Total Common Shares Outstanding |